A novel approach in clinical immunosuppression monitoring: Drug lymphocyte level

Experimental and Clinical Transplantation

Volumn 5, Issue 2, 2007, Pages 643-648

  Barbari, Antoine ^a   Masri, Marwan ^b   Stephan, Antoine ^a   Rizk, Sylvana ^b   Younan, Farida ^a  

^a Lebanese Institute for Renal Disease   (Lebanon)

^b TransMedical Research Institute   (Lebanon)

Author keywords

Bioactivity; Bioavailability; Immunity; Pharmacodynamic; Pharmacokinetic

Indexed keywords

ANTILIPEMIC AGENT; CALCINEURIN; CALCINEURIN INHIBITOR; CELL RECEPTOR; CYCLOPHILIN B; CYCLOSPORIN A; CYTOSINE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; RAPAMYCIN; S6 KINASE; TACROLIMUS; TYROSINE;

AGE; ARTICLE; BINDING AFFINITY; BINDING SITE; BODY MASS; CELL COMPOSITION; CELL LEVEL; CLINICAL PRACTICE; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FOOD INTAKE; GENETIC POLYMORPHISM; HEMATOCRIT; HEREDITY; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; INDIVIDUALIZATION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE; METHODOLOGY; PATIENT CARE; PATIENT MONITORING; PHARMACOGENETICS; PROTEIN EXPRESSION; SEX DIFFERENCE; TARGET CELL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL AVAILABILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES;

EID: 38549105116     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit. 1989;11(3):246-248.
2. Barbari A, Stephan A, Kamel G, Kilany H, Masri MA. Experience with new cyclosporine formulations: Consupren and Neoral in renal transplant patients. Transplant Proc. 1997;29(7):2941-2944.
3. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68(1):55-62.
4. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 2003;76(6):903-908.
5. Marcén R, Pascual J, Tato A, et al. Comparison of C0 and C2 cyclosporine monitoring in long-term renal transplant recipients. Transplant Proc. 2003;35(5):1780-1782.
6. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)- based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036-1042.
7. Hauser AI, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16:1501-1511.
8. Barbari A, Masri MA, Stephan A, et al. Cyclosporine lymphocyte versus whole blood pharmacokinetic monitoring: correlation with histological findings. Transplant Proc. 2001;33(5):2782-2785.
9. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelvemonth evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25(5):609-622.
10. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem. 1998;44(2):428-432.
11. Barbari A, Stephan A, Masri MA, et al. Mycophenolic acid plasma trough level: correlation with clinical, outcome. Exp Clin Transplant. 2005;3(2):355-360.
12. Barbari A, Masri M, Stephan A, et al. Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation. Exp Clin Transplant. 2005;3(1):293-300.
13. Barbari A, Masri M, Stephan A, et al. Cyclosporine lymphocyte maximum level monitoring in cle novo kidney transplant patients: a prospective study. Exp Clin Transplant. 2006;4(1):400-405.
14. Barbari A, Masri M, Stephan A, et al. Tacrolimus whole blood versus lymphocyte trough level: Correlation with immune response. (MESOT abstract]. Exp Clin Transplant. 2006;4(2):58.
15. Barbari A, Masri M, Stephan A, et al. Cyclosporine A whole blood vs lymphocyte maximum concentration: correlation with immune response. [MESOT abstract]. Exp Clin Transplant. 2006;4(2):58.
16. Barbari A, Masri M, Stephan A, et al. Tacrolimus lymphocyte vs blood trough level monitoring in de novo kidney transplant patients: Clinical relevance. [MESOT abstract]. Exp Clin Transplant. 2006;4(2):36.
17. Masri M, Rizk S, Barbari A, Stephan A, Kamei G Rost M. An assay for the determination of sirolimus levels in the lymphocyte of transplant patients. Transplant Proc. 2007;39(4):1204-1206.
18. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest. 1995;96(3):1254-1260.
19. Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest. 1997;100(7):1894-1901.
20. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol. 2001;12(5): 1059-1071.
21. Londono MC, Cirera I, Brunet M, Millan O, Martorell J, Rimola A. Calcineurin inhibitors (CNI) Pharmacodynamics in liver transplantation. [ESOT abstract No. 243]. Transplant Int. 2005:109.
22. Hartmann B, Schmid G, Graeb C, et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int. 2005;68(6):593-2598.
23. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant. 2005;5(2):207-217.
24. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211-2221.
25. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006;28(1):39-44.
26. Rosano TG. Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients. Clin Chem. 1985;31(3):410-412.
27. Denys A, Allain F, Masy E, Dessaint JP, Spik G. Enhancing the effect of secreted cyclophilin B on immunosuppressive activity of cyclosporine. Transplantation. 1998;65(8):1076-1084.
28. Denys A, Allain F, Foxwell B, Spik G. Distribution of cyclophilin B- binding sites in the subsets of human peripheral blood lymphocytes. Immunology. 1997;91(4):609-617.
29. Barbari A, Stephan A, Mash M, et al. Parameters affecting temporal variations of CsA lymphocyte maximum levels in stable de novo, kidney Transplant patients. [MESOT abstract]. Exp Clin Transplant. 2004; 2(2): 12.
30. Barbari A, Stephan A, Masri MA, Kamel G, Kilani H, Barakeh A. Chronic graft dysfunction: donor factors. Transplant Proc. 2001;33(5):2695-2698.
31. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356(9242): 1667-1671.
32. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3):186-200.
33. Fredericks S, Holt DW, MacPhee IA. The pharmacogenetics of immuno-suppression for organ transplantation: a route tp individualization of drug administration. Am J Pharmacogenomics. 2003;3(5):291-301.
34. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001;72(5):777-786.
35. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation. 2002;74(11):1560-1567.
36. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant. 2004;4(8):1308-1314.
37. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and funttion in sirolimus-treated patients. Transplantation. 2003;75(7):998-1003.
38. Stephan A, Barbari A, Kamel,G, et al. Sirolimus side effects. The different experience of a single centre. [MESOT abstract]. Exp Clinic Transplant. 2004;2(2):38.
39. Barbari A, Stephan A, Mash M. Calcineurin Inhibitors-free immunosuppression: Risks and benefits. Saudi J of Kid Dis Transplant. March 2007;18(1):1-23.